State Street Corp Acurx Pharmaceuticals, Inc. Transaction History
State Street Corp
- $2.59 Trillion
- Q2 2025
A detailed history of State Street Corp transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 43,466 shares of ACXP stock, worth $192,554. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,466
Previous 43,466
-0.0%
Holding current value
$192,554
Previous $16,000
37.5%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ACXP
# of Institutions
37Shares Held
2.71MCall Options Held
62.9KPut Options Held
56.9K-
Armistice Capital, LLC New York, NY1.08MShares$4.78 Million0.01% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$1.62 Million0.08% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$648,5690.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA146KShares$644,7280.0% of portfolio
-
Morgan Stanley New York, NY106KShares$470,4700.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $51.2M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...